Urine Proteomics Solutions

Normal human urine contains a large amount of proteins and peptides. In addition to the large amount of proteins found in normal urine, the protein/peptide composition is influenced by a variety of factors such as gender, age, diet, lifestyle and physiological conditions and can change significantly over time. Urine is one of the most valuable biological fluids for biomarkers discovery, because it is present in considerable quantities in almost all patients and its collection is simple and non-invasive compared to other biological fluids.

With technological advances in mass spectrometry (MS) platforms, clinical proteomics is one of the most rapidly growing areas of biomedical research. Urine proteomics is a popular area of clinical proteomics and is an ideal source for noninvasive disease biomarkers discovery. Technologies for proteomics is rapidly developing and high-throughput, systematic analysis and identification of urine proteins have begun to use proteomics. It has also been applied to explain physiological metabolism, toxicology and many disease processes. In particular, proteins in urinary diseases can be secreted directly into the urine via the urethra, thus allowing the identification of disease pathogenesis and finding biomarkers for early diagnosis. However, changes in protein/peptide composition make the characteristics of normal or diseased urine proteome more complicated, which in turn makes the identification of protein/peptide biomarkers in urine more difficult, especially the analysis of large cohort samples.

Our Quantitative Urine Proteomics Service

DIA technology is becoming more and more popular in urine proteome research because of its unbiased full-coverage scanning mode, quantitative stability and reproducibility that cannot be surpassed by traditional techniques.

We apply advanced 4D or DIA-based discovery proteomics analysis technology to urinary protein analysis, which reveals a large amount of disease-related functional information of large-scale urine samples, so as to help you identify meaningful biomarkers related to the diagnosis, prognosis, monitoring and treatment of specific diseases. Our urine quantitative proteomics service is ideal for long-term projects or projects with large size of samples which require accurate and reproducible quantitation. We also offer highly multiplexed targeted proteomics with absolute quantification for customized panels of proteins. Please contact us for more details.

The workflow for urinary protein biomarker discovery. (Watcharin Loilome et al. PLoS One. 2019)

Advantages

• High accuracy: QC CV as low as 25% for large projects
• High throughput, more than 9000 proteins can be identified at once
• Quantitatively identify nearly all detectable molecules, covering low abundance proteins/peptides
• High repeatability, increased by 30% and up to 90%
• Complete and comprehensive sample information storage in the first analysis
• Standard data and advanced data analysis
• Cost-effective

Sample Requirements

Report

• Experimental steps
• Relevant experiment parameters
• Mass spectrometry spectra
• Raw data
• Proteomics analysis results

Since we provide DIA technology service, we have accumulated a lot of experience not only in detecting large cohort conventional samples but also providing one-stop service of DIA+PRM+machine learning for biomarker studies, tumor-based proteomic typing and large clinical sample proteomics analysis based on next-generation chromatography (Evosep DIA). Please contact us for a free consultation.

References:

1. Watcharin Loilome et al. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis. PLoS One (2020) 14 8.
2. Sebastian Virreira Winter et al. Urinary proteome profiling for stratifying patients with familial Parkinson's disease. EMBO Mol Med (2021) 13: e13257